Medical application of compound

By using 12-O-tiglylphorbol-13-isobutyrate compound as the active ingredient, the problem of limited therapeutic effects of existing pancreatic cancer and melanoma has been solved, significantly inhibited cancer cell proliferation, and provided more effective treatment options, which are especially suitable for in early and late stage patients.

CN118924726APending Publication Date: 2024-11-12SHANGHAI UNIV OF T C M
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410920888.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing pancreatic cancer and melanoma treatments have limited effectiveness in some patients, especially in patients with early stage melanoma and those who do not meet the surgical criteria, requiring more effective inhibitory drugs.

Method used

Using 12-O-tiglylphorbol-13-isobutyrate compound as active ingredient, it is used to prepare drugs to prevent and treat pancreatic cancer and melanoma, inhibit cancer cell proliferation through cytotoxic effects, and combines pharmaceutically acceptable salts and drug carriers, and adopts conventional Routes of administration such as oral administration, injection, etc.

Benefits of technology

Significantly inhibiting the proliferation of pancreatic cancer cells and melanoma cells provides more effective therapeutic options, especially in early and late stage patients, and improves therapeutic effects through the use of pharmaceutical compositions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924726A_ABST
    Figure CN118924726A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a compound or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing and treating pancreatitis or melanoma. The compound disclosed by the invention can be used for preventing and treating pancreatitis or melanoma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, in particular to the application of a compound. Background Art

[0002] Although the development of radiotherapy, chemotherapy and tumor targeted therapy has contributed to the treatment of pancreatic cancer, surgery is still the only chance for pancreatic cancer patients to achieve long-term survival. However, 30%-55% of patients do not meet the conditions for early surgery when diagnosed. Melanoma is an invasive skin cancer with the characteristics of early metastasis, strong invasiveness and poor prognosis. For patients with early melanoma, extended resection of the primary lesion is performed, and targeted and immunotherapy are often used for patients in the late stage. Targeted drugs can effectively prolong the survival of melanoma patients, but they are still prone to drug resistance. Therefore, there is still a need to explore more effective drugs to inhibit pancreatic cancer and melanoma. Summary of the invention

[0003] The object of the present invention is to provide a new use of a compound.

[0004] Specifically, the first aspect of the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and treating pancreatic cancer:

[0005]

[0006] In a preferred embodiment, the above compound is used as the sole active ingredient in the preparation of a drug for preventing and treating pancreatic cancer.

[0007] The second aspect of the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and treating melanoma:

[0008]

[0009] In a preferred embodiment, the above compound is used as the sole active ingredient in the preparation of a drug for preventing and treating melanoma.

[0010] The details of various aspects of the present invention will be described in detail in the following sections. The features, objectives and advantages of the present invention will become more apparent through the following description and the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 This is the cytotoxicity curve of the monomer compound 12-O-tiglylphorbol-13-isobutyrate on human pancreatic cancer cells BxPC3, Miapaca2, and SW1990.

[0012] Figure 2The cytotoxicity curve of the monomer compound 12-O-tiglylphorbol-13-isobutyrate on human melanoma cells A375 and mouse melanoma cells B16F10. DETAILED DESCRIPTION

[0013] The present invention provides the use of the following compound of formula (I) in the preparation of a drug for preventing and treating pancreatic cancer or melanoma:

[0014]

[0015] 12-O-tiglylphorbol-13-isobutyrate (12-tiglylphorbol-13-isobutyrate),

[0016] The molecular formula is: C 29 H 40 O8, molecular weight: 516.6 g / mol, CAS: 92214-54-5.

[0017] The present invention also includes all pharmaceutically acceptable salts corresponding to the above compounds. These salts can be formed by a positively charged part (amino group) in the compound and a negatively charged acid (e.g., hydrochloric acid) with opposite charge; including but not limited to salts generated with the following acids: hydrochloric acid, sulfuric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfurous acid, nitric acid, carbonic acid, boric acid, selenious acid, phosphomolybdic acid, phosphorous acid, citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, D-lactic acid, L-lactic acid, DL-lactic acid, oxalic acid, sulfonic acid, benzenesulfonic acid, substituted benzenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, phthalic acid, tartaric acid, malonic acid, succinic acid, fumaric acid, citric acid, benzoic acid or substituted benzoic acid.

[0018] The compounds of the present invention can be purchased through commercial channels, and their purity meets the pharmaceutical standards.

[0019] The compounds of the present invention can be used alone or in the form of a pharmaceutical composition. The pharmaceutical composition comprises the compounds of the present invention as active ingredients and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition of the present invention contains 0.1 to 99.9% by weight of the compounds of the present invention as active ingredients. The "pharmaceutically acceptable carrier" will not destroy the pharmaceutical activity of the compounds of the present invention, and its effective amount, i.e., the amount that can play the role of a pharmaceutical carrier, is non-toxic to the human body.

[0020] The pharmaceutically acceptable carriers include, but are not limited to, phospholipids, aluminum stearate, aluminum oxide, ion exchange materials, self-emulsifying drug delivery systems, Tween or other surfactants, serum proteins, buffer substances such as phosphates, aminoacetic acid, sorbic acid, water, salts, electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, magnesium silicate, partial glyceride mixtures of saturated fatty acids, and the like.

[0021] Other commonly used pharmaceutical excipients include binders (such as microcrystalline cellulose), fillers (such as starch, glucose, anhydrous lactose and lactose beads), disintegrants (such as cross-linked PVP, cross-linked sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), lubricants (such as magnesium stearate), as well as absorption enhancers, adsorption carriers, flavoring agents, sweeteners, excipients, diluents, wetting agents, etc.

[0022] The compounds of the present invention and their pharmaceutical compositions can be prepared according to conventional methods in the art and can be administered by enteral, parenteral or topical routes. Oral preparations include capsules, tablets, oral liquids, granules, pills, powders, pills, ointments, etc.; parenteral preparations include injections, etc.; topical preparations include creams, patches, ointments, sprays, etc. Oral preparations are preferred.

[0023] The compounds of the present invention and their pharmaceutical compositions can be administered orally, sublingually, intramuscularly or subcutaneously, intravenously, urethrally, vaginally, and the like.

[0024] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually performed under normal conditions or according to the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, proportions, or parts are by weight.

[0025] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0026] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in this patent specification can be used in combination with any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.

[0027] Example 1 Study on the inhibition of proliferation of pancreatic cancer cells BxPC3, SW1990, Miapaca3 and melanoma cells A375, B16F10 by the monomer compound 12-O-tiglylphorbol-13-isobutyrate

[0028] Materials and Methods

[0029] SpectraMax190 microplate reader (Molecular Corporation, USA); Leica DMi1 microscope (Leica Corporation, Germany); dimethyl sulfoxide (DMSO, batch number BCBZ1685, Sigma, Switzerland); 96-well plate (Nest Biotech, China)

[0030] 1. Cell Culture

[0031] BxPC3, SW1990, Miapaca3, and A375 cells were placed in DMEM complete medium containing 10% FBS and 1% PS, and B16F10 cells were placed in 1640 complete medium containing 10% FBS and 1% PS. They were cultured in a 37°C, 5% CO2 incubator. When the cells entered the logarithmic growth phase, the next experiment was carried out.

[0032] 2. Cell plating and grouping

[0033] BxPC3, SW1990, Miapaca3, and A375 cells were seeded at 5000 cells / well in a 96-well plate using DMEM medium; B16F10 cells were seeded at 5000 cells / well in a 96-well plate using 1640 medium, 100 μL per well, 5 replicate wells were set for each concentration group, and the plates were placed in a 37°C 0.5% CO2 incubator overnight.

[0034] BxPC3, SW1990, and Miapaca3 were stimulated with culture medium or culture medium containing different concentrations (0, 0.001, 0.01, 0.1, 1, 10 μM) of monomeric compounds for 24 and 48 h, respectively. A375 and B16F10 cells were stimulated with culture medium or culture medium containing different concentrations (0, 0.001, 0.01, 0.1, 1, 10 μM) of monomeric compounds for 24, 48, and 72 h, respectively.

[0035] 10 μL of MTT reagent was added to each well and mixed, incubated in an incubator for 4 h, and finally the absorbance OD value was measured at a wavelength of 570 nm using an enzyme reader.

[0036] 3. Result analysis:

[0037] Take the average value of 5 replicate wells.

[0038] Cell survival rate % = (OD value of drug-treated group ÷ OD value of control group) * 100%.

[0039] Half maximal inhibitory concentration (IC 50 ): drug concentration when T / C=50%. T: OD value of drug-added group, C: OD value of control group.

[0040] result:

[0041] 1. Cytotoxic effect of monomeric compound 12-O-tiglylphorbol-13-isobutyrate on human pancreatic cancer cells BxPC3, Miapaca2, and SW1990 Monomeric compound 12-O-tiglylphorbol-13-isobutyrate has a good inhibitory effect on cell proliferation of human pancreatic cancer cells BxPC3, Miapaca2, and SW1990 at 24 and 48 hours (see Figure 1 ), IC values ​​of 24 and 48 h for human pancreatic cancer cells BxPC3 50 The IC values ​​of human pancreatic cancer cell Miapaca2 at 24 and 48 h were 0.9651 and 0.5613 μM respectively. 50 The IC values ​​for human pancreatic cancer cells SW199048h were 0.8175 and 0.5194 μM respectively. 50 0.5613 μM;

[0042] 2. Cytotoxicity of the monomer compound 12-O-tiglylphorbol-13-isobutyrate on human melanoma cells A375 and mouse melanoma cells B16F10

[0043] The monomer compound 12-O-tiglylphorbol-13-isobutyrate has a good inhibitory effect on the proliferation of human melanoma A375 cells at 24, 48, and 72 hours. 50 The results are 0.5824, 0.0417, and 0.0186 μM, respectively; it has a good inhibitory effect on the proliferation of mouse melanoma cells B16F10 at 72 h, with an IC50 of 0.2383 μM (see Figure 2 ).

[0044] Cell experiments have shown that the monomer compound of the present invention has an obvious effect of inhibiting the proliferation of pancreatic cancer cells and melanoma cells.

[0045] The various aspects of the present invention have been described above. However, it should be understood that, without departing from the spirit of the present invention, equivalent changes and modifications may be made by those skilled in the art, and the changes and modifications also fall within the scope of the claims of the present application.

Claims

1. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and treating pancreatic cancer:

2. Use of the compound or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The compound is used as the sole active ingredient in preparing medicine for preventing and treating pancreatic cancer.

3. Use of the compound of formula (I) or its pharmaceutically acceptable salt in the preparation of a drug for preventing and treating melanoma:

4. Use of the compound or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The compound is used as the sole active ingredient for preparing medicine for preventing and treating melanoma.